• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Pharma stocks fall on Trump’s proposal to cut NIH budget

March 16, 2017 By Sarah Faulkner

Pharma stocks fall on Trump's proposal to cut NIH budgetThe Trump budget plan to slash more than 18% from the budget for the National Institutes of Health sent pharmaceutical stocks down today on Wall Street as investors reacted to the proposal.

The budget proposal, released today, would cut the NIH budget by $5.8 billion, to $25.9 billion – an 18.3% cut. The proposal would also introduce “a major reorganization of NIH’s Institutes and Centers to help focus resources on the highest priority research and training activities.”

The proposal would eliminate the Fogarty International Center, a global health-focused organization, and consolidate the Agency for Healthcare Research & Quality. It also includes “other consolidations and structural changes across NIH organizations and activities” and “reduces administrative costs and rebalance[s] Federal contributions to research funding.”

Investors reacted by sending pharma and other healthcare related stocks down today:

COMPANY SHARE PRICE % CHANGE
Boston Scientific (NYSE:BSX) $24.27 -1.6%
C.R. Bard (NYSE:BCR) $248.69 -0.8%
Merck (NYSE:MRK) $64.09 -0.9
Becton Dickinson & Co. (NYSE:BDX) $181.00 -1.9%
Amgen (NSDQ:AMGN) $178.26 -2.4%
Abbott (NYSE:ABT) $44.83 -1.1%
Pfizer (NYSE:PFE) $34.34 -0.8%
Medtronic (NYSE:MDT) $82.21 -1.3%
Biogen (NSDQ:BIIB) $14.93 -5.1%
Gilead Sciences (NSDQ:GILD) $68.39 -0.1%
Johnson & Johnson (NYSE:JNJ) $128.16 -0.6%

Filed Under: Featured, Policy, Wall Street Beat Tagged With: Abbott Laboratories, Amgen, Becton Dickinson, Biogen Idec, Boston Scientific, C.R. Bard, Gilead Sciences, johnsonandjohnson, Medtronic, Merck, Pfizer Inc.

IN CASE YOU MISSED IT

  • Shareholder lawsuit over BD’s Alaris pumps recall moves forward
  • Embecta stock soars on first full-quarter results after BD spinoff
  • Abbott will spend $450M to up FreeStyle Libre production in Ireland
  • Better Therapeutics Q2 beats Street as it prepares to submit diabetes therapy for FDA review
  • Study backs Fluidx embolic device for vessel filling

Primary Sidebar

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Need Drug Delivery Business News in a minute? We Deliver!
Drug Delivery Enewsletters get you caught up on all the mission critical news you need in med tech. Sign up today.

Signup for the newsletter

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing & Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts
Add us on FacebookFollow us on TwitterConnect with us on LinkedIn

Copyright © 2022 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Advertise | Privacy Policy | RSS